Diagnosis & Disease Information

VICTRELIS (boceprevir) 200mg capsules by Merck

Victrelis Approved for Chronic Hepatitis C

Merck announced that the FDA has approved Victrelis (boceprevir), a hepatitis C virus protease inhibitor, for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients ≥18 years of age with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy.

Viramune XR Approved for HIV-1 Infection in Adults

Boehringer Ingelheim Pharmaceuticals announced that the FDA has approved Viramune XR (nevirapine) extended-release tablets, a one-pill, once-daily (400mg) formulation of nevirapine for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

Zostavax Gains Expanded Indication

Merck announced that Zostavax (varicella zoster vaccine, live, attenuated) has gained an expanded indication for the prevention of herpes zoster (shingles) in individuals 50-59 years of age.

Phase 2 Study of Telaprevir for HCV-HIV Co-infection

Vertex Pharmaceuticals announced data from its Phase 2 study of telaprevir in combination with pegylated-interferon and ribavirin compared to pegylated-interferon and ribavirin alone for the treatment of patients who are infected with both genotype 1 hepatitis C virus (HCV) and human immunodeficiency virus (HIV), also known as HCV-HIV co-infection.